{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0","upperLimit":"0","value":"0"}]}],"title":"Complete Response"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"1.2","upperLimit":"15.9","value":"5.8"}]}],"title":"Partial Response"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"74.2","upperLimit":"94.4","value":"86.5"}]}],"title":"Stable Disease"}],"denoms":[{"counts":[{"groupId":"OG000","value":"52"}],"units":"Participants"}],"description":"The percentage of patients who achieved a complete, partial or stable response prior to surgery as assessed by Response Evaluation Criteria in Solid Tumours criteria (RECIST). RECIST criteria is described here: http://ctep.cancer.gov/protocolDevelopment/docs/recist\\_guideline.pdf.","dispersionType":"95% Confidence Interval","groups":[{"description":"Patients receive oral imatinib mesylate once daily. Treatment continues for 8 weeks in the absence of disease progression. Patients with disease progression are considered for immediate surgical resection. Otherwise, after 8 weeks, patients undergo surgical resection to debulk all gross tumor. Two to four weeks after surgery, patients receive oral imatinib mesylate once daily for 2 years.","id":"OG000","title":"Imatinib Mesylate"}],"paramType":"NUMBER","populationDescription":"Eligible patients who started study treatment","reportingStatus":"POSTED","timeFrame":"Pretreatment and prior to surgery (at 4-10 weeks, based on surgery timing)","title":"Rates of Objective Response (Complete, Partial, and Stable)","type":"SECONDARY","unitOfMeasure":"percentage of participants"}